



MOLEAC Pte. Ltd.

11 Biopolis way • #09-08 Helios • 138667 Singapore
Tel + 65 64 78 94 30 • Fax + 65 64 78 94 35 • www.moleac.net
Company Regn No : 200210152D G.S.T. Regn No : 20-0210152-D

Prof. Michel Lazdunski receives Gold Medal from the Jung Foundation for his work on ion channels.

SINGAPORE, January 31, 2011

We are happy to announce that Prof. Michel Lazdunski, vice president research of Moleac, has been awarded one of the most prestigious international awards - the 2011 Gold Medal of the Jung Foundation for Science and Research, for his work on ion channels.



Prof. Michel Lazdunski dedicated his entire career to outstanding medical research. In 2011, the Jung Foundation wanted to reward his work in the field of ion channels, which have led to fundamental discoveries in the fields of physiology, pathology and pharmacology. Over the last 30 years, Prof. Michel Lazdunski and his team, using a highly diverse and sophisticated pharmacological arsenal, have elucidated the molecular properties of the structure and functioning of ion channels, shedding a new light on the role of these ion channels and other ion transport systems in a wide range of diseases and pathological conditions.

The Jung Foundation Gold Medal for Science and Research is one of the most prestigious in the world. Yet Prof. Lazdunski has already been awarded with a Gold Medal from the CNRS, the highest French scientific distinction as well as several other prestigious awards, such as the Grand Prix of the French Academy of Sciences for biological research (Charles Leopold Mayer Prize), the International Society for Cardiac Research Prize, the Bristol-Myers Foundation Neuroscience Award, the Athena Foundation - Institut de France Prize, the Grand Prix of the French Academy of Sciences for research of importance to the medical field and the Grand Prix of the French Foundation for Medical Research.

Michel Lazdunski is active in a number of academic and medical international initiatives. Currently he is a member of the Alzheimer Plan, several foundations and committees including the Fondation Leduc, Academia Europaea, French Academy of Sciences and the Belgian Academy of Medicine.



Meanwhile, he is leading two important research activities. The first activity is related to pain management – especially pain of unclear origins, related to the terminal phases of cancer or post-surgical neuropathies. His second research project pertains to the field of cerebrovascular accidents and neurological pathologies. His team based at the CNRS (National French Research Institute) in France is actively involved in several researches conducted on NeuroAiD, the first post-stroke recovery treatment. The recent pharmacology data published in *Neuropharmacology* have already confirmed neurorestorative properties of NeuroAiD™ and its efficacy in improving post-stroke recovery. The team is now focusing on confirming indication expansions for NeuroAiD™ to meet the underserved needs of sufferers in stroke prevention, Alzheimer disease and other ailments of the central and peripheral nerve systems.

About Jung Foundation

The Ernst Jung foundation, established in 1967, is dedicated to the promotion of medical research. The foundation awards annual prizes to scholars for their achievements in research and the practical applications that derive from their results.

About Moleac

<http://www.moleac.net>

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide.

About NeuroAiD

<http://www.neuroaid.com>

NeuroAiD is a stroke treatment to help stroke patients achieve faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries.

Contact details:

Kasia Kaminska

Telephone: +65 8533 0652

Email: kasia.kaminska@moleac.net